U.S. manufacturers of vaccine against Asian influenza did better than they had expected: last week, well ahead of schedule, two companies turned out half a million shots and (with an eye to public relations) allocated most of the vaccine to meet civilian demand. Philadelphia's National Drug Co. was ready with 260,000 straight anti-Asian shots, plus 60,000 shots of polyvalent vaccine, compounded for use against three types of flu recently current, including the Asian. Lederle Laboratories of Pearl River, N.Y. had churned out 180,000 doses, set aside half for the armed forces (which will do their own testing, thus hold up distribution...
To continue reading:
or
Log-In
